Last reviewed · How we verify
KITE-753
KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.
KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. Used for Relapsed or refractory B-cell malignancies (Phase 3 development).
At a glance
| Generic name | KITE-753 |
|---|---|
| Sponsor | Kite, A Gilead Company |
| Drug class | CAR-T cell therapy |
| Target | Tumor-associated antigen (specific target not publicly disclosed in detail) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
KITE-753 involves engineering a patient's T cells to express a chimeric antigen receptor (CAR) targeting a defined tumor-associated antigen, enabling the modified T cells to recognize, proliferate, and destroy malignant cells. The CAR construct combines antigen recognition with T cell activation domains to drive potent anti-tumor immunity. This autologous cell therapy is manufactured on a patient-by-patient basis and reinfused to establish durable anti-tumor responses.
Approved indications
- Relapsed or refractory B-cell malignancies (Phase 3 development)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (PHASE3)
- Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KITE-753 CI brief — competitive landscape report
- KITE-753 updates RSS · CI watch RSS
- Kite, A Gilead Company portfolio CI